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Serum Cardiac Troponin I Concentrat ion in Dogs with Precapi l lary
and Postcapi l lary Pulmonary Hypertension
C. Guglielmini, C. Civitella, A. Diana, M. Di Tommaso, M. Cipone, and A. Luciani
Background: Pulmonary hypertension (PH) is a disease condition leading to right-sided cardiac hypertrophy and, eventually,
right-sided heart failure. Cardiac troponin I (cTnI) is a circulating biomarker of cardiac damage.
Hypothesis: Myocardial damage can occur in dogs with precapillary and postcapillary PH.
Animals: One hundred and thirty-three dogs were examined: 26 healthy controls, 42 dogs with mitral valve disease (MVD)
without PH, 48 dogs with pulmonary hypertension associated with mitral valve disease (PH-MVD), and 17 dogs with precap-
illary PH.
Methods: Prospective, observational study. Serum cTnI concentration was measured with a commercially available
immunoassay and results were compared between groups.
Results: Median cTnI was 0.10 ng/mL (range 0.10–0.17 ng/mL) in healthy dogs. Compared with the healthy population,
median serum cTnI concentration was increased in dogs with precapillary PH (0.25 ng/mL; range 0.10–1.9 ng/mL; P o .001)
and in dogs with PH-MVD (0.21 ng/mL; range 0.10–2.10ng/mL; P o .001). Median serum cTnI concentration of dogs with
MVD (0.12 ng/mL; range 0.10–1.00 ng/mL) was not significantly different compared with control group and dogs with PH-
MVD. In dogs with MVD and PH-MVD, only the subgroup with decompensated PH-MVD had significantly higher cTnI
concentration compared with dogs with compensated MVD and PH-MVD. Serum cTnI concentration showed significant
modest positive correlations with the calculated pulmonary artery systolic pressure in dogs with PH and some echocardio-
graphic indices in dogs with MVD and PH-MVD.
Conclusions and Clinical Importance: Serum cTnI is high in dogs with either precapillary and postcapillary PH. Myocardial
damage in dogs with postcapillary PH is likely the consequence of increased severity of MVD.
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P
ulmonary hypertension (PH) refers to an increase in
pulmonary arterial pressure and is defined by sys-
tolic and diastolic pulmonary artery pressure 425 and
15mmHg, respectively, at rest.1–5 Different cardiovascu-
lar modifications can accompany PH, including right
ventricular hypertrophy (RVH) and dilatation, right atri-
al enlargement, and, eventually, right-sided heart failure.
The clinical classification of PH in humans includes 5
categories: pulmonary arterial hypertension caused by
vascular diseases affecting pulmonary arterioles; PH as-
sociated with pulmonary venous hypertension caused by
left-sided cardiac diseases; PH associated with lung dis-
eases, hypoxemia or both; PH associated with thrombo-
embolic disorders; and PH associated with miscellaneous
disorders.6 In dogs, the most common causes of PH in-
clude heartworm infection, mitral valve disease (MVD),
and respiratory tract disease, while primary pulmonary
arterial hypertension is rare.1–5,7–13,a A more simplified
classification, still used in the dog, distinguishes precap-
illary PH from postcapillary PH, which is PH associated
with left-sided cardiac disorders.2,4,5,12
Cardiac catheterization is the gold standard for defin-
itive measurement of pulmonary arterial pressure.
Noninvasive evaluation of pulmonary artery pressure
may be obtained by Doppler echocardiography.1–5,12 In
the absence of pulmonic stenosis, systolic or diastolic
pulmonary artery pressure can be estimated by applying
the modified Bernoulli equation (Dp 5 4  velocity2) to
the peak velocity of tricuspid regurgitation (TR) or
pulmonic insufficiency (PI), respectively. Therefore, the
widespread use of Doppler echocardiography has greatly
enhanced the identification of dogs with PH in the recent
years.12
Right ventricular failure resulting in low cardiac out-
put is the main cause of death in human patients with
PH.14 Severe respiratory distress is the main cause of
death or euthanasia in dogs with PH.4,13 Severe PH in
humans results in lower systemic blood pressure and this
may decrease coronary perfusion gradient.15At the same
time, increased right ventricular intramural pressure can
disturb the physiological pattern of right ventricular
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myocardial perfusion.16Cardiac troponin T (cTnT) and I
(cTnI) are myocardial proteins that are released in the
extracellular space when myocardial cellular injury and
necrosis occur.17 In particular, the circulating concentra-
tion of cardiac troponins is proportional to the extent of
myocardial injury.17,18 There is a high homology of the
nucleotide and amino-acid sequences of human and ca-
nine cTnI, allowing human commercial cTnI analyzers to
be used to measure cTnI in dogs.19 Reference range val-
ues of circulating cTnI concentration have been
published in healthy dogs (ie,o 0.03 to 0.07 ng/mL with
a mean of 0.02 ng/mL and o 0.05 to 0.12 ng/mL with a
mediano 0.05 ng/mL).20,21 Increased circulating level of
cardiac troponins have been demonstrated in dogs with
different cardiac disorders including MVD, dilated card-
iomyopathy, pericardial effusion, congestive heart
failure (CHF), gastric dilatation-volvulus, babesiosis,
subaortic stenosis, arrhythmogenic right ventricular
cardiomyopathy of Boxers, and blunt chest trauma.22–32
Increased levels of circulating cardiac troponins have
been demonstrated in humans with pulmonary thrombo-
embolism (PTE) and PH.16,33–36 Furthermore, patients
with PTE and elevated cardiac troponins have a worse
prognosis than those without troponins elevation. To the
best of the authors’ knowledge, circulating cardiac
troponins have not been evaluated in dogs with PH.
The aim of the present study was to evaluate serum
cTnI concentrations in dogs with precapillary PH and pul-
monary hypertension associated with mitral valve disease
(PH-MVD), and to compare them with those observed in
healthy dogs and dogs with MVD without PH.
Methods
Animals and Selection Criteria
The protocol of this prospective study was approved by the Eth-
ical Committees of the University of Teramo and Bologna. Dogs
presented to the cardiology service of the Veterinary Teaching Hos-
pital of the University of Teramo and Bologna from October 2003
to November 2008 were eligible for entry into the study. During this
time period, healthy animals from hospital employees and students
were also enrolled. Animals represented a wide range of ages and
breeds. Enrollment was based on owner consent and the availability
of the dog for ECG, survey thoracic radiography, and echocardio-
graphic examination. In each center, the same experienced operator
(C.G. and M.C.) evaluated the thoracic radiographs and echocar-
diograms. Based on results of the above exams, dogs were assigned
to 1 of 4 groups according to the following criteria:
(1) Healthy dogs: dogs with normal cardiac auscultation, 6-lead
ECG, survey thoracic radiography, 2-dimensional (2D) andM-
mode echocardiogram, and color flow and spectral Doppler
examination.
(2) MVD without PH: dogs with a left and right apical systolic
murmur; negative serology for canine heartworm antigen;
thickened, nodular, or prolapsing mitral valve leaflets on 2D
echocardiography without echocardiographic and Doppler ev-
idence of pulmonic stenosis; mild-to-severe mitral valve
regurgitation and low velocity TR (ie,  2.4m/s) and/or PI (ie,
 1.9m/s) on Doppler echocardiography. Dogs with MVD but
without detectable TR, PI, or both were not included in this
group, because pulmonary artery pressure cannot be deter-
mined by the above Doppler echocardiographic technique in
these dogs.
(3) PH-MVD: dogs with a left and right apical systolic murmur;
negative serology for canine heartworm antigen; thickened,
nodular, or prolapsing mitral valve leaflets on 2D echocardiog-
raphy without echocardiographic and Doppler evidence of
pulmonic stenosis; mild-to-severe mitral valve regurgitation,
peak TR velocity  2.5m/s (corresponding to a systolic pres-
sure gradient of 25mmHg) and/or PI velocity  2.0m/s
(corresponding to a diastolic pressure gradient of 16mmHg)
on Doppler echocardiography.
(4) Precapillary PH: dogs with clinical signs of dyspnea, tachypnea,
ascites, syncope, lethargy, or exercise intolerance, and a right-
sided systolic murmur; right-sided cardiac hypertrophy without
echocardiographic and Doppler evidence of other congenital or
acquired cardiovascular diseases; peak TR  2.5m/s and/or PI
velocity  2.0m/s on Doppler echocardiography.
Cardiac Evaluation
Echocardiographic and echo-Doppler examinations were per-
formed without sedation with 2 echocardiographic machinesb,c
equipped with 2.8–3.8 and 4.5–6.5MHz, and 2.5–3.5 and 5.0–
7.5MHz phased array transducers. Standard echocardiographic
scan planes were employed to obtain a definitive diagnosis in each
dog.37 Ventricular measurements were obtained from the right pa-
rasternal location during 2D-guided M-mode echocardiography.
Measurements of the left atrial diameter (LA) and aortic diameter
(Ao) were obtained with a 2D method. In dogs with MVD and PH-
MVD, presence or absence of RVH was subjectively assessed as
previously described.1,38 In brief, RVH was deemed if the right ven-
tricular chamber size was greater than one third of the size of the left
ventricle on M-mode measurements obtained from the right para-
sternal location and/or the right ventricular wall thickness was
greater than one half of the left ventricular free wall. Furthermore,
the following echocardiographic parameters were selected for suc-
cessive statistical evaluation: left ventricular diameter at diastole
(LVDd), left ventricular diameter at systole (LVDs), LA, and Ao. In
particular, the following echocardiographic ratio indices were con-
sidered: LVDd :Ao, LVDs :Ao, fractional shortening (FS), and
LA :Ao.
In dogs with PH, the pulmonary artery systolic pressure (PASP)
was calculated by adding the estimated right atrial pressure (RAP)
to the Doppler derived systolic right ventricle to RAP gradient. The
latter was calculated by applying the modified Bernoulli equation
(Dp 5 4  velocity2) to the peak velocity of TR obtained by the left
parasternal 4-chamber view. The estimated RAP was 5mmHg in
dogs with a nonenlarged right atrium, 10mmHg in dogs with an en-
larged right atrium but without right-sided congestive heart failure
(R-CHF), and 15mmHg in dogs with R-CHF.39 According to the
International Small Animal Cardiac Health Council (ISACHC)
classification score,40 dogs with MVD and PH-MVD were further
subdivided into 2 groups: dogs with compensated (ISACHC class Ia
and Ib) and decompensated (ISACHC class II and III) CHF. Fur-
thermore, the prevalent type of CHF (ie, left-sided congestive heart
failure [L-CHF] or R-CHF) was recorded.
Data Collection and cTnI Analysis
Blood samples were collected in 5mL serum blood tubes and
centrifuged within 30minutes after collection. The serum obtained
was separated and stored at ÿ801C for batched cTnI analysis. Sam-
ple storage varied from 1 month to 6 months. Samples were thawed
only once, at the time of analysis. The measurement of serum cTnI
concentration was performed with a commercially available
immunometric assayd with a lower detection limit of 0.1 ng/mL.
This assay has been validated for dogs in the laboratory of the Vet-
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erinary Clinical Department of the University of Bologna41 and
showed an intraassay and interassay variabilityo 10%. The assay
has been previously used in 2 studies evaluating cTnI concentration
in dogs with cardiac disorders.27,32
Statistical Analysis
Normally distributed data are reported as mean  SD and non-
normally distributed data are expressed as median and ranges. The
1-way analysis of variance test was used to analyze normally
distributed continuous data (age, echocardiographic, and echo-
Doppler data) followed by Tukey’s posttest for multiple compari-
sons, and the chi-square test was used for comparison of categorical
data. For nonnormally distributed data (body weight and serum
cTnI concentration), the Kruskal-Wallis test was employed for
comparison among groups followed by Dunn’s multiple compari-
son posttest.
In dogs with MVD, the odds ratio (OR) was calculated to eval-
uate the association between the presence or absence of PH and
development of L-CHF or R-CHF.
In dogs with precapillary PH and PH-MVD, the rank correlation
by means of Spearman’s r coefficient was used to assess the degree
of association between serum cTnI concentration and calculated
PASP. In dogs with MVD and PH-MVD, Spearman’s r rank cor-
relation coefficient was used to assess the degree of association
between serum cTnI concentration and the echocardiographic indi-
ces LVDd :Ao, LVDs :Ao, FS, and LA :Ao.
Serum cTnI concentrations o 0.1 ng/mL were statistically ana-
lyzed for 0.1 ng/mL.
All statistical analyses were performed by use of statistical soft-
ware packages.e,f The minimum level of significance was chosen for
Po .05.
Results
Patients
The study population included 133 dogs of different
breeds, 66 males (2 castrated) and 67 females (13 spayed).
Of these, 26 dogs were healthy, 42 had MVD without
PH, 48 had PH-MVD, and 17 had precapillary PH.
The signalments of each patient group are presented in
Table 1. Dogs with MVD, PH-MVD, and precapillary
PH were older compared with control dogs (P o .001,
Po .001, and Po .01, respectively). Dogs with precap-
illary PH were younger compared with dogs with MVD
(Po .01) and PH-MVD (Po .001). No statistical differ-
ence was found between dogs with MVD and PH-MVD
regarding body weight and age.
Causes of precapillary PH included chronic respira-
tory disorders (n 5 5; chronic tracheobronchial diseases,
3 dogs; chronic interstitial lung disease, 2 dogs), heart-
worm infection (n 5 4), PTE (n 5 4), congenital cardiac
diseases (ie, reversed patent ductus arteriosus, n 5 2),
and angiostrongylosis (n5 1). In 1 dog, left-sided cardiac
disease was excluded but the etiology of PH could not be
determined.
Cardiac Evaluation
In dogs with MVD, PH was more prevalent in dogs
with decompensated CHF (n 5 33/41, 81%) compared
with dogs with compensated CHF (n 5 15/49, 31%) (P
o .001). In dogs with MVD and decompensated CHF,
R-CHF was more prevalent in dogs with PH (n 5 17/33,
52%) compared with dogs without PH (n 5 2/8, 25%),
but no association was found between presence or ab-
sence of PH and type of CHF (OR 5 3.2, 95%
confidence interval 5 0.6–18.2, P 5 .34). The overall
prevalence of R-CHF in dogs with precapillary and post-
capillary PH was 47% (n5 8/17) and 35% (n 5 17/48),
respectively. Similarly, RVH was more prevalent in dogs
with PH-MVD (n 5 14, 29%) compared with dogs with
MVD (n 5 1, 2%) (P o .01). In particular, dogs with
compensated and decompensated PH-MVD had signifi-
cantly higher prevalence of RVH (n 5 3 and 11,
respectively) compared with dogs with compensated
MVD (n 5 0, P o .05 and P o .001, respectively) but
not to dogs with decompensated MVD (n 5 1, P 5 .90
and P 5 .46, respectively).
Echocardiographic indices in dogs withMVD and PH-
MVD are shown in Table 2. Dogs with decompensated
MVD and PH-MVD had significantly higher LVDd :Ao
(Po .01) compared with dogs with compensated MVD.
The LA :Ao was significantly higher in dogs with decom-
pensated MVD and PH-MVD compared with dogs with
compensated MVD (P o .001). The LA :Ao was also
significantly higher in dogs with decompensated MVD
(Po .05) and PH-MVD (Po .001) compared with dogs
with compensated PH-MVD. No statistical difference
Table 1. Signalment in 133 dogs.
Healthy (n5 26) MVD (n5 42) PH-MVD (n 5 48) Precapillary PH (n5 17)
Sex
Male 9 24 26 7
Female 17 18 22 10
Age (years) 4.1  2.2 10.7  3.4,‰ 11.4  2.7,w 7.5  4.2#
Body weight (kg) 23 (5–38) 9 (3–50) 8.2 (3–43) 15 (1.6–45)
Data are listed as the mean  standard deviation and median (range) for age and body weight, respectively.
Po .05 compared with healthy dogs.
Po .001 compared with healthy dogs.
‰Po .01 compared with dogs with precapillary PH.
wPo .001 compared with dogs with precapillary PH.
#Po .01 compared with healthy dogs.
MVD, mitral valve disease without pulmonary hypertension; PH-MVD, pulmonary hypertension associated with MVD; PH, pulmonary
hypertension.
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was found regarding LVDs :Ao and FS among the four
subgroups.
Trivial PI was found in 5 healthy dogs. High velocity
(ie, 4 2m/s) PI was found in 8 dogs, 1 with PH-MVD
and 7 with precapillary PH. All of these dogs had high
velocity (ie, 4 2.5m/s) TR peak velocity. Values of TR
peak velocity, Doppler-derived pressure gradient be-
tween the right ventricle and atrium, estimated RAP,
and calculated PASP in dogs with MVD, PH-MVD, and
precapillary PH are shown in Table 3. Significantly
higher (P o .001) TR peak velocity, Doppler-derived
pressure gradient between the right ventricle and atrium,
RAP, and calculated PASP were found in dogs with pre-
capillary PH and PH-MVD compared with dogs with
MVD without PH. Furthermore, dogs with precapillary
PH had significantly higher (Po .001) TR peak velocity,
Doppler-derived pressure gradient between the right ven-
tricle and atrium, and calculated PASP compared with
dogs with PH-MVD.
cTnI
In healthy dogs, cTnI was below the detection limit of
the test in 19/26 dogs (73%) and the median serum cTnI
concentration was 0.10 ng/mL (range, 0.10–0.17 ng/mL)
with the upper 95th percentile at 0.15 ng/mL (the lower
limit of detection for the cTnI assay is 0.1 ng/mL). The
median cTnI concentration was 0.12 ng/mL (range, 0.10–
1.00 ng/mL) in dogs with MVD, with n 5 22 (52%) of
dogs having cTnI levels40.10 ng/mL. The median cTnI
concentration was 0.21 ng/mL (range, 0.10–2.10 ng/mL)
in dogs with PH-MVDwith n5 34 (71%) of dogs having
cTnI levels 40.10 ng/mL. The median cTnI concentra-
tion was 0.25 ng/mL (range, 0.10–1.90 ng/mL) in dogs
with precapillary PH, with n 5 14 (82%) of dogs having
cTnI levels40.10 ng/mL.
Results of serum cTnI concentration in the 4 different
groups of dogs are shown in Figure 1 and Table 4. No
statistical difference was found in serum cTnI concentra-
tion between healthy dogs and MVD dogs, between dogs
with MVD and PH-MVD, and between dogs with pre-
capillary PH and PH-MVD. Dogs with precapillary PH
and PH-MVD had serum cTnI concentration signifi-
cantly higher compared with healthy dogs (P o .001).
Median cTnI concentration was also higher in dogs
with precapillary PH compared with dogs with MVD
(P o .05). Considering all dogs with MVD as a unique
group, thus including also dogs with PH-MVD, serum
cTnI of these dogs was significantly higher compared
with healthy dogs (P o .001). Results of serum cTnI
Table 2. Echocardiographic data in 90 dogs with mitral valve disease.
C-MVD (n5 34) D-MVD (n5 8) C-PH-MVD (n5 15) D-PH-MVD (n5 33)
LVDd :Ao 2.1  0.5 2.9  0.5 2.3  0.7 2.7  0.8
LVDs :Ao 1.2  0.4 1.6  0.4 1.4  0.5 1.5  0.6
FS (%) 40  10 45  10 39  5 43  11
LA :Ao 1.7  0.4 2.7  0.5,‰ 1.9  0.5 2.6  0.7,#
RVH
Yes/no 0/34 1/7 3/12 11/22
Data are reported as the mean  standard deviation.
Po .05 compared with C-MVD.
Po .01 compared with C-MVD.
Po .001 compared with C-MVD.
‰Po .05 compared with C-PH-MVD.
#Po .001 compared with C-PH-MVD.
C-MVD, compensated mitral valve disease without pulmonary hypertension (ISACHC class Ia and Ib); D-MVD, decompensated mitral
valve disease without pulmonary hypertension (ISACHC class II and III); C-PH-MVD, compensated mitral valve disease associated with
pulmonary hypertension; D-PH-MVD, decompensated mitral valve disease associated with pulmonary hypertension. LVDd, left ventricular
diameter at diastole; LVDs, left ventricular diameter at systole; Ao, aortic diameter; FS, fractional shortening; LA, left atrial diameter; RVH,
right ventricular hypertrophy.
Table 3. Echo-Doppler data in 42 dogs with mitral valve disease without pulmonary hypertension and 65 dogs with
pulmonary hypertension.
MVD (n5 42) PH-MVD (n5 48) Precapillary PH (n5 17)
TR Vmax (m/s) 1.9  0.5 3.1  0.5
 3.8  0.9,#
Dp (mmHg) 16  6 40  12 62  30,#
RAP (mmHg) 8.2  2.7 13.4  2.3 12.4  2.6
PASP (mmHg) 24  6 53  13 74.5  31,#
Data are reported as the mean  standard deviation.
Po.001 compared with MVD.
#Po.001 compared with PH-MVD.
MVD, mitral valve disease; PH-MVD, Pulmonary hypertension associated with mitral valve disease; PH, pulmonary hypertension; TR
Vmax, tricuspid regurgitation maximal velocity; Dp, right atrium-to-right ventricle pressure gradient; RAP, estimated right atrial pressure;
PASP, pulmonary artery systolic pressure (Dp1 RAP).
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concentration after subdivision of dogs with MVD and
MVD-PH according to the ISACHC classification (ie,
dogs with compensated and decompensated CHF) are
shown in Figure 2. Dogs with decompensated PH-MVD
had median cTnI concentration (0.38 ng/mL, range,
0.10–2.10 ng/mL) significantly higher compared with
healthy dogs (P o .001), dogs with compensated MVD
(0.10 ng/mL, range, 0.10–0.72 ng/mL P o .001), and
compensated PH-MVD (0.10 ng/mL, range, 0.10–
0.52 ng/mL P o .01), but no statistical difference was
found compared with dogs with decompensated MVD
(0.45 ng/mL, range, 0.10–1.00 ng/mL). Dogs with pre-
capillary PH had significantly higher serum cTnI
concentration compared with dogs with compensated
MVD (Po .05). No statistical difference was found be-
tween dogs with precapillary PH and dogs with
decompensated MVD and PH-MVD.
A significant modest positive correlation was found be-
tween serum cTnI concentration and the calculated PASP
in all dogs with PH (ie, those with either precapillary and
postcapillary) (r5 0.46, Po .001). In particular, the cir-
culating cTnI concentration and calculated PASP had a
significant moderate positive correlation in dogs with pre-
capillary PH (r5 0.56, Po .05) and a significant modest
positive correlation in dogs with PH-MVD (r 5 0.44, P
o .01). A significant modest positive correlation was also
found between serum cTnI concentration and the echo-
cardiographic indices LA :Ao (r 5 0.37, P o .001),
LVDd :Ao (r 5 0.24, P 5 .03), and LVDs :Ao (r 5
0.22, P 5 .04), in dogs with MVD and MVD-PH, but no
correlation existed between serum cTnI concentration
and FS (r5 ÿ0.01, P 5 .92).
Discussion
Dogs with precapillary PH had significantly higher
value of TR maximal velocity and, consequently, PASP
compared with dogs with PH-MVD, because no differ-
ence was found in the estimated RAP between the 2
groups of dogs. These findings support that precapillary
PH is usually associated with a greater increase in pul-
monary arterial pressure compared with postcapillary
PH in the dog.1,2,4,13 A positive correlation was found
between cTnI concentration and severity of PH, as
recently observed in dogs with precapillary PH experi-
mentally induced via acute PTE.42 Thus, increased
pulmonary arterial pressure could be an inciting factor
for myocardial damage in dogs with either precapillary
and postcapillary PH.
Significantly increased LA and, partially, LVDd were
found in dogs with decompensated MVD and PH-MVD
compared with their counterparts with compensated val-
Fig. 1. Serum cardiac troponin I (cTnI) concentrations obtained
from 26 healthy dogs, 42 dogs with mitral valve disease (MVD)
without pulmonary hypertension, 48 dogs with pulmonary hyper-
tension associated with mitral valve disease (PH-MVD), and 17
dogs with precapillary PH. The horizontal line in each box repre-
sents the median value. The boxes represent the interquartile range
(25th to 75th percentile). Whiskers represent the 5th and 95th per-
centiles. Outliers are plotted separately as dots. Statistical
difference (P o .001) with control dogs; ‰Statistical difference (P
o .05) with MVD dogs; NS, not significant.
Table 4. cTnI concentrations (ng/mL) in 133 dogs.
Sample Size Median Range
Healthy 26 0.10 0.10–0.17
MVD 42 0.12 0.10–1.00
PH-MVD 48 0.21 0.10–2.10
Precapillary PH 17 0.25 0.10–1.90
MVD, mitral valve disease without pulmonary hypertension; PH-
MVD, mitral valve disease associated with pulmonary hyperten-
sion; PH, pulmonary hypertension.
Fig. 2. Serum cardiac troponin I (cTnI) concentrations obtained
from 26 healthy dogs, 34 dogs with compensated (ISACHC class Ia
and Ib) mitral valve disease (C-MVD), 8 dogs with decompensated
(ISACHC class II and III) mitral valve disease (D-MVD), 15 dogs
with compensated mitral valve disease associated with pulmonary
hypertension (C-PH-MVD), 33 dogs with decompensated mitral
valve disease associated with pulmonary hypertension (D-PH-
MVD), and 17 dogs with precapillary PH. The horizontal line in
each box represents the median value. The boxes represent the in-
terquartile range (25th to 75th percentile). Whiskers represent the
5th and 95th percentiles. Outliers are plotted separately as dots.
Statistical difference (P o .01) with control dogs; Statistical
difference (Po .001) with control dogs; ‰Statistical difference (Po
.001) with C-MVD; ‰‰Statistical difference (Po .05) with C-MVD;
zStatistical difference (P o .01) with C-PH-MVD; zzStatistical
difference (Po .05) with C-PH-MVD; NS, not significant.
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vular disease, and PH was more prevalent in dogs with
decompensated CHF. These findings support that PH
has a tendency to develop in the advanced stages of
MVD, although nearly a third of dogs with PH-MVD
had compensated CHF, as previously reported.12 Dogs
with PH-MVD had significantly higher cTnI concentra-
tion compared with dogs with MVD without PH
indicating an increased myocardial damage in the former
dogs. However, after subdividing all dogs with MVD (ie,
either those with and without PH) according to the
ISACHC classification score, only dogs with decompen-
sated PH-MVD had significantly increased serum cTnI
concentration compared with control dogs and dogs with
compensated MVD, either with or without PH. On the
contrary, cTnI did not differ between dogs with precap-
illary PH and dogs with decompensated MVD and PH-
MVD. Furthermore, dogs with decompensated MVD,
with or without PH, did not show any statistical differ-
ence in their cTnI concentration. Regarding the
prevalent type of CHF, the development of PH in dogs
with decompensated MVD was not associated with an
increased prevalence of R-CHF compared with L-CHF.
Irrespective of the underlying cause (ie, precapillary or
postcapillary), right ventricular failure often represents
the final common pathway portending a poor prognosis
in humans with PH.43 The prevalence of RVH was sig-
nificantly higher in dogs with PH-MVD (33.3%)
compared with dogs with MVD without PH, and was
similar to the prevalence of right heart chambers enlarge-
ment (32.6%) observed in a previous study on dogs with
MVD and Doppler-derived evidence of PH.12 The afore-
mentioned findings suggest that decompensated CHF is
the primary inciting factor for myocardial damage in
dogs with MVD followed by PH and RVH. Considering
all dogs with MVD enrolled in the present study (ie, ei-
ther those with and without PH), their overall cTnI
concentration was higher compared with control dogs.
In a previous study, dogs with compensated and decom-
pensatedMVD had higher cTnI concentration compared
with healthy dogs.28 In another study, dogs with MVD
had higher cTnI concentration compared with healthy
dogs, but dogs with compensated MVD did not show
significant difference in cTnI levels compared with con-
trol dogs,27 similarly to dogs of the present study. In the
former study, a chemiluminescent sandwich ELISA tech-
nique with a lower limit of detection of 0.02 ng/mL was
employed. In the latter study the same immunometric
chemiluminescent assay system employed in our study
was used. Different levels of sensitivity between the 2
cTnI assays may explain the above discrepancy, because
results obtained with different cTnI analyzers do not
agree sufficiently to be interchangeable.44
The cTnI concentration had a modest but significant
correlation with the left atrial size and left ventricular
systolic and diastolic diameter in dogs with MVD and
PH-MVD. These positive correlations are similar to
those previously observed in dogs with MVD and card-
iomyopathy.28 Indeed, increased LA :Ao is the most
significant variable for cardiac-related death in dogs with
MVD and a significant positive correlation between left
atrial and ventricular dimensions and PASP has already
been reported in the dog.12,45,46 Previously demonstrated
associations between increased troponins concentration
and severe prognosis in dogs with cardiac disorders in-
clude a decreased survival time in cardiomyopathy and
negative prognostic indicator in acute myocardial dam-
age associated with gastric dilatation-volvolus.28,29
Different pathophysiological mechanisms may be re-
sponsible for increased circulating cTnI concentration in
dogs with PH. Cardiac troponins are specific markers of
cardiomyocyte injury which are detectable when either
the right or left ventricle is injured.18 However, release
from the right ventricle and subsequent troponins blood
levels are low compared with those of the left vent-
ricle because of differences in muscular mass.47 Pressure
overload of the right ventricle because of increased pul-
monary arterial resistance leads to decreased myocardial
perfusion and oxygen supply and, eventually, right ven-
tricular dysfunction.33 Furthermore, increased stress to
the right ventricle is the cause of troponin increase in
pulmonary embolism and increased cTnI concentration
was associated with echocardiographic signs of right ven-
tricular dilatation in humans with acute pulmonary
embolism (APE).33,48–50 Thus, circulating troponins
evaluation is considered highly sensitive for the early de-
tection of minor myocardial cells injury in pulmonary
embolism associated with right ventricular dysfunc-
tion.33 Similarly, detectable serum cTnT is a strong
independent marker of risk of death in patients with
chronic precapillary PH, and patients with PTE and ele-
vated cTnT have a worse prognosis than those without
cTnT elevation.16,51 At the same time, severe PH induces
lower systemic blood pressure and hypoxemia from per-
fusion-ventilation mismatch, thus resulting in decreased
coronary perfusion gradient.15,51 In APE, myocardial
necrosis can be caused by right ventricular infarction,
which may be secondary to APE or can accompany this
condition, even if coronary artery show no pathology.50
Thus, the use of cardiac troponins for risk stratification
of patients with APE may be limited, owing to the differ-
ent mechanism of myocardial damage compared with
that in patients with acute coronary syndrome.51 In par-
ticular, because of the complex release kinetics and
clearance mechanisms of cardiac troponins, their circu-
lating concentration in APE strictly depends on time
elapsed from the onset of clinical signs.51,52 Therefore,
the use of cTnI in risk stratification of APE might
be limited to patients presenting early after onset of clin-
ical signs.52 In dogs, disease conditions associated
with precapillary PH mainly act through a chronic
pathophysiological mechanism, because acute throm-
boembolic events are difficult to distinguish from other
cardio-respiratory disorders.53,54 Reduced ventricular
perfusion of both ventricles in the setting of precapillary
PH as well as ongoing subclinical myocyte degeneration
because of deterioration of clinical status in dogs with
postcapillary PH-MVD are the likely causes of mild in-
creases of cTnI observed in dogs with PH of the present
study.
There are several limitations of this study that need
emphasis. First, pulmonic or tricuspid valve regurgita-
tion is not always detected in dogs with PH.5,8,55 Thus, it
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is possible that some healthy dogs with PH but without
detectable high velocity right-sided valvular regurgita-
tion were included in the control group. Other
echocardiographic techniques have been proposed for
the indirect diagnosis of PH (ie, PW-Doppler evaluation
of the pulmonic systolic flow profile, measurement of
Doppler-derived systolic time intervals of pulmonary ar-
tery flow, and use of Doppler tissue imaging)1,5,55 but
they are less commonly employed in the clinical setting
compared with the Doppler evaluation of TR and PI ve-
locity. However, PHwas considered very unlikely in dogs
without clinical, radiographic, and echocardiographic
evidence of cardio-respiratory disorders. Second, dogs
with MVD are also predisposed to development of con-
current broncho-pulmonary diseases leading to increased
vascular resistance and, eventually, precapillary PH.12
These diseases may be clinically silent and difficult to de-
tect on thoracic radiographs because changes are masked
by pulmonary edema.12 Careful examination of thoracic
radiographs of dogs with PH-MVD was particularly
aimed to rule out concurrent respiratory disorders, al-
though different cause-and-effect mechanisms of PH
could not completely ruled out in dogs with postcapil-
lary PH. Third, the type, degree, and distribution of
myocardial damage were not assessed in dogs with PH.
However, the accurate assessment of myocardial changes
would have required histological examination of post-
mortem tissue specimens or endomyocardial biopsy
specimens, which was beyond the scope of our study. Fi-
nally, age and breed matching of the enrolled dogs would
have strengthened the results of this prospective study,
because a modest but significant positive correlation has
been demonstrated between cTnI and age in the dog and
some Terriers are predisposed to chronic pulmonary dis-
eases leading to precapillary PH.5,8,28
Footnotes
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